Related Experiment Video
Updated: Sep 14, 2026
Development of Obliterative Bronchiolitis in a Murine Model of Orthotopic Lung Transplantation
Published on: July 10, 2012
Liposomal amphotericin B in three lung transplant recipients. The Groningen Lung Transplantation Group
G P Mannes1, W van der Bij, W J de Boer
1Department of Pulmonary Diseases, University Hospital, Groningen, The Netherlands.
Background:
Opportunistic fungal infections are an important cause of morbidity and mortality in solid organ transplant recipients. Conventional therapy with amphotericin B is often restricted by toxicity. However, side effects and toxicity of liposomal amphotericin B are reported to be limited.
Methods:
Three lung transplant recipients with proven infections with Aspergillus fumigatus were treated with liposomal amphotericin B.
Results:
Therapy with liposomal amphotericin B in our patients showed more side effects and (nephro)toxicity than suggested by previous reports. However, it did not result in cessation of treatment prematurely, and patients were able to complete the antifungal therapy with good clinical success.
Conclusions:
Treatment with liposomal amphotericin B represents an advance from conventional amphotericin B therapy.
Insights
Liposomal amphotericin B offers an alternative for invasive fungal infections in transplant patients. While some toxicity was observed, it allowed for successful completion of antifungal therapy.
Area of Science:
- Mycology
- Transplant Medicine
- Infectious Diseases
Background:
- Opportunistic fungal infections pose significant risks to solid organ transplant recipients.
- Conventional amphotericin B therapy is limited by toxicity.
- Liposomal amphotericin B is considered to have a better safety profile.
Observation:
- Three lung transplant recipients with Aspergillus fumigatus infections were treated with liposomal amphotericin B.
- Observed side effects and nephrotoxicity were more pronounced than previously reported.
Findings:
- Despite increased toxicity, liposomal amphotericin B treatment did not lead to premature cessation.
- Patients successfully completed antifungal therapy, achieving good clinical outcomes.
- Liposomal amphotericin B demonstrated clinical efficacy in treating invasive aspergillosis.
Implications:
- Liposomal amphotericin B represents a viable treatment option for invasive fungal infections in transplant recipients.
- Further research may be warranted to optimize dosing and management strategies to mitigate toxicity.
- This approach offers an advance over conventional amphotericin B therapy.
